Chronic, programmed polypeptide delivery from an implanted, multireservoir microchip device

被引:158
作者
Prescott, JH [1 ]
Lipka, S [1 ]
Baldwin, S [1 ]
Sheppard, NF [1 ]
Maloney, JM [1 ]
Coppeta, J [1 ]
Yomtov, B [1 ]
Staples, MA [1 ]
Santini, JT [1 ]
机构
[1] MicroCHIPS Inc, Bedford, MA 01730 USA
关键词
D O I
10.1038/nbt1199
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 [微生物学]; 0836 [生物工程]; 090102 [作物遗传育种]; 100705 [微生物与生化药学];
摘要
Implanted drug delivery systems are being increasingly used to realize the therapeutic potential of peptides and proteins. Here we describe the controlled pulsatile release of the polypeptide leuprolide from microchip implants over 6 months in dogs. Each microchip contains an array of discrete reservoirs from which dose delivery can be controlled by telemetry.
引用
收藏
页码:437 / 438
页数:2
相关论文
共 11 条
[1]
Chronic (60-week) toxicity study of DUROS leuprolide implants in dogs [J].
Cukierski, MJ ;
Johnson, PA ;
Beck, JC .
INTERNATIONAL JOURNAL OF TOXICOLOGY, 2001, 20 (06) :369-381
[2]
Where a pill won't reach [J].
Langer, R .
SCIENTIFIC AMERICAN, 2003, 288 (04) :50-57
[3]
Small-scale systems for in vivo drug delivery [J].
LaVan, DA ;
McGuire, T ;
Langer, R .
NATURE BIOTECHNOLOGY, 2003, 21 (10) :1184-1191
[4]
In vivo delivery of BCNU from a MEMS device to a tumor model [J].
Li, YW ;
Duc, HLH ;
Tyler, B ;
Williams, T ;
Tupper, M ;
Langer, R ;
Brem, H ;
Cima, MJ .
JOURNAL OF CONTROLLED RELEASE, 2005, 106 (1-2) :138-145
[5]
Electrothermally activated microchips for implantable drug delivery and biosensing [J].
Maloney, JM ;
Uhland, SA ;
Polito, BF ;
Sheppard, NF ;
Pelta, CM ;
Santini, JT .
JOURNAL OF CONTROLLED RELEASE, 2005, 109 (1-3) :244-255
[6]
PHARMACOKINETICS OF ONCE-A-MONTH INJECTABLE MICROSPHERES OF LEUPROLIDE ACETATE [J].
OKADA, H ;
INOUE, Y ;
HEYA, T ;
UENO, H ;
OGAWA, Y ;
TOGUCHI, H .
PHARMACEUTICAL RESEARCH, 1991, 8 (06) :787-791
[7]
A controlled-release microchip [J].
Santini, JT ;
Cima, MJ ;
Langer, R .
NATURE, 1999, 397 (6717) :335-338
[8]
Catheter survival during long-term insulin therapy with an implanted programmable pump [J].
Scavini, M ;
Galli, L ;
Reich, S ;
Eaton, RP ;
Charles, MA ;
Dunn, FL ;
Micossi, P ;
Torri, M ;
Petrella, G ;
Galimberti, G ;
Cristallo, M ;
Vai, S ;
Pozza, G ;
Olsen, C ;
Turner, D ;
Nolleman, C ;
LavinTompkins, J ;
Selam, JL ;
Haardt, MJ ;
Dorange, C ;
Jeandidier, N ;
Ortega, F ;
Boivin, S ;
Nathan, D ;
Larkin, M ;
McKitrick, C ;
Schwarz, S ;
Fisher, J ;
Kipnes, S ;
Walz, B ;
Vague, P ;
Reeves, ML ;
Goudner, M ;
Thomson, GP ;
Jaffiol, C ;
Renard, E ;
Lauton, D ;
JacquesApostol, D ;
Bringer, J ;
Tauber, JP ;
HanaireBroutin, H ;
ReesJones, R ;
Adolff, S ;
Bays, HA ;
Pfeifer, M ;
Clarke, D ;
Irsigler, K ;
Feinboch, C ;
Hutter, R ;
Mendel, H .
DIABETES CARE, 1997, 20 (04) :610-613
[9]
Shastri V. Prasad, 2003, Current Pharmaceutical Biotechnology, V4, P331
[10]
Controlled drug delivery: therapeutic and pharmacological aspects [J].
Urquhart, J .
JOURNAL OF INTERNAL MEDICINE, 2000, 248 (05) :357-376